Lund, Sweden, 2015-05-19 08:29 CEST (GLOBE NEWSWIRE) --
A new important BSI-study is to be presented at the 2015 ASCO-congress (American Society of Clinical Oncology) held in Chicago, USA. The congress, which is the world’s largest in oncology, gathers approximately 30 000 oncology-experts from all over the World.
Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and on-going controversies in the field. Science sessions present the latest important research in oral or poster format.
”The BSI-study is one out of merely three biomarker studies accepted for presentation at this year’s ASCO-congress. Getting the approval from the world’s largest and highest ranked congress in oncology serves as further proof of the growing interest in BSI within the oncology community,” comments Magnus Aurell, CEO, EXINI Diagnostics AB.
Details on the BSI-presentation:
”Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer” authored by Aseem Anand et al, Lund University (Lund, Sweden).
The presentation abstract is available at:
http://abstracts.asco.org/156/AbstView_156_149539.html
More on Bone Scan Index (BSI):
BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate cancer.
Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI boneBSI is the only software capable of calculating the BSI-value.
www.bonescanindex.org
www.exini.com/software/exini-bone-bsi/
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North and has about 1000 shareholders. Consensus acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
